Does the media prefer FLGT or MD?

In the previous week, Fulgent Genetics had 1 more articles in the media than Pediatrix Medical Group. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for Pediatrix Medical Group. Fulgent Genetics' average media sentiment score of 1.68 beat Pediatrix Medical Group's score of 0.75 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pediatrix Medical Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASTH or FLGT?

In the previous week, Fulgent Genetics had 2 more articles in the media than Astrana Health. MarketBeat recorded 4 mentions for Fulgent Genetics and 2 mentions for Astrana Health. Fulgent Genetics' average media sentiment score of 1.68 beat Astrana Health's score of 1.45 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrana Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor FLGT or GRDN?

In the previous week, Fulgent Genetics and Fulgent Genetics both had 4 articles in the media. Fulgent Genetics' average media sentiment score of 1.68 beat Guardian Pharmacy Services' score of 0.04 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Guardian Pharmacy Services 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, FLGT or PGNY?

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulgent Genetics $322.67M 1.76 -$60.51M -$2.82 N/A Progyny $1.29B 1.66 $58.52M $0.92 30.27

Is FLGT or PGNY more profitable?

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% Progyny 6.00% 15.98% 10.65%

Does the media refer more to FLGT or PGNY?

In the previous week, Progyny had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 11 mentions for Progyny and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.68 beat Progyny's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Progyny 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGL or FLGT?

In the previous week, Agilon Health had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Agilon Health and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.68 beat Agilon Health's score of 0.73 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilon Health 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Fulgent Genetics (FLGT) Competitors

$20.65 +0.20 (+0.98%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$20.65 0.00 (0.00%)

As of 09/14/2026 07:30 PM Eastern

Compare

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

Should you buy Fulgent Genetics stock or one of its competitors? Fulgent Genetics's main competitors and comparable companies include Pediatrix Medical Group (MD), Astrana Health (ASTH), Guardian Pharmacy Services (GRDN), Progyny (PGNY), and Agilon Health (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Fulgent Genetics compare to Pediatrix Medical Group?

Fulgent Genetics (NASDAQ:FLGT) and Pediatrix Medical Group (NYSE:MD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Fulgent Genetics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Pediatrix Medical Group has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 97.7% of Pediatrix Medical Group shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 1.8% of Pediatrix Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Fulgent Genetics had 1 more articles in the media than Pediatrix Medical Group. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for Pediatrix Medical Group. Fulgent Genetics' average media sentiment score of 1.68 beat Pediatrix Medical Group's score of 0.75 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pediatrix Medical Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pediatrix Medical Group has a net margin of 8.96% compared to Fulgent Genetics' net margin of -26.05%. Pediatrix Medical Group's return on equity of 20.05% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Pediatrix Medical Group	8.96%	20.05%	8.15%

Fulgent Genetics presently has a consensus price target of $27.50, indicating a potential upside of 33.17%. Pediatrix Medical Group has a consensus price target of $26.60, indicating a potential downside of 1.15%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Pediatrix Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pediatrix Medical Group	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Pediatrix Medical Group has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.76	-$60.51M	-$2.82	N/A
Pediatrix Medical Group	$1.91B	1.14	$165.39M	$2.09	12.88

Summary

Pediatrix Medical Group beats Fulgent Genetics on 9 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to Astrana Health?

Astrana Health (NASDAQ:ASTH) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Astrana Health has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Astrana Health has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.69	$22.49M	$0.82	48.29
Fulgent Genetics	$322.67M	1.76	-$60.51M	-$2.82	N/A

In the previous week, Fulgent Genetics had 2 more articles in the media than Astrana Health. MarketBeat recorded 4 mentions for Fulgent Genetics and 2 mentions for Astrana Health. Fulgent Genetics' average media sentiment score of 1.68 beat Astrana Health's score of 1.45 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Astrana Health currently has a consensus target price of $49.43, suggesting a potential upside of 24.82%. Fulgent Genetics has a consensus target price of $27.50, suggesting a potential upside of 33.17%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Astrana Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.8% of Astrana Health shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 20.3% of Astrana Health shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Astrana Health has a net margin of 1.05% compared to Fulgent Genetics' net margin of -26.05%. Astrana Health's return on equity of 10.30% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Astrana Health beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Fulgent Genetics (NASDAQ:FLGT) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Guardian Pharmacy Services has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.76	-$60.51M	-$2.82	N/A
Guardian Pharmacy Services	$1.46B	1.58	$49.22M	$1.03	45.20

Guardian Pharmacy Services has a net margin of 4.50% compared to Fulgent Genetics' net margin of -26.05%. Guardian Pharmacy Services' return on equity of 29.97% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Guardian Pharmacy Services	4.50%	29.97%	16.18%

Fulgent Genetics currently has a consensus price target of $27.50, suggesting a potential upside of 33.17%. Guardian Pharmacy Services has a consensus price target of $43.83, suggesting a potential downside of 5.85%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Guardian Pharmacy Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Guardian Pharmacy Services	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fulgent Genetics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

In the previous week, Fulgent Genetics and Fulgent Genetics both had 4 articles in the media. Fulgent Genetics' average media sentiment score of 1.68 beat Guardian Pharmacy Services' score of 0.04 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Guardian Pharmacy Services	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Guardian Pharmacy Services beats Fulgent Genetics on 9 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to Progyny?

Fulgent Genetics (NASDAQ:FLGT) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.76	-$60.51M	-$2.82	N/A
Progyny	$1.29B	1.66	$58.52M	$0.92	30.27

In the previous week, Progyny had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 11 mentions for Progyny and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.68 beat Progyny's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Progyny	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Progyny has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Progyny	6.00%	15.98%	10.65%

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fulgent Genetics presently has a consensus price target of $27.50, indicating a potential upside of 33.17%. Progyny has a consensus price target of $34.36, indicating a potential upside of 23.39%. Given Fulgent Genetics' higher possible upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Progyny beats Fulgent Genetics on 13 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Agilon Health?

Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Agilon Health had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Agilon Health and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.68 beat Agilon Health's score of 0.73 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilon Health	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Agilon Health currently has a consensus target price of $100.18, indicating a potential upside of 8.71%. Fulgent Genetics has a consensus target price of $27.50, indicating a potential upside of 33.17%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.27
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agilon Health has a net margin of -3.92% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-3.92%	-119.38%	-16.85%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Agilon Health has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

48.1% of Fulgent Genetics shares are owned by institutional investors. 2.5% of Agilon Health shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fulgent Genetics has lower revenue, but higher earnings than Agilon Health. Fulgent Genetics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.92B	0.26	-$391.35M	-$14.27	N/A
Fulgent Genetics	$322.67M	1.76	-$60.51M	-$2.82	N/A

Summary

Fulgent Genetics beats Agilon Health on 9 of the 16 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$562.69M	$9.85B	$7.16B	$14.31B
Dividend Yield	N/A	2.61%	2.57%	11.71%
P/E Ratio	-7.32	34.23	273.30	25.37
Price / Sales	1.76	4.92	617.12	74.54
Price / Cash	N/A	24.78	28.42	34.96
Price / Book	0.58	5.42	10.42	6.24
Net Income	-$60.51M	$313.45M	$3.49B	$358.08M
7 Day Performance	2.23%	0.42%	-1.16%	-0.70%
1 Month Performance	11.26%	-0.22%	0.56%	-2.76%
1 Year Performance	-6.05%	16.86%	20.18%	6.72%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.8466 of 5 stars	$20.65 +1.0%	$27.50 +33.2%	-5.6%	$562.69M	$322.67M	N/A	1,315	Positive News
MD Pediatrix Medical Group	1.7516 of 5 stars	$26.96 -0.3%	$26.60 -1.3%	+61.4%	$2.19B	$1.91B	12.90	4,315	Analyst Upgrade
ASTH Astrana Health	4.0331 of 5 stars	$38.10 -1.0%	$49.43 +29.7%	+32.8%	$2.12B	$3.84B	46.46	3,000	Positive News
GRDN Guardian Pharmacy Services	1.5487 of 5 stars	$42.47 +4.2%	$43.83 +3.2%	+57.1%	$2.11B	$1.45B	41.23	3,600
PGNY Progyny	4.366 of 5 stars	$27.15 +4.7%	$34.36 +26.6%	+23.7%	$2.08B	$1.31B	29.51	310	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

How does Fulgent Genetics compare to Pediatrix Medical Group?

Summary

How does Fulgent Genetics compare to Astrana Health?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Summary

How does Fulgent Genetics compare to Progyny?

Summary

How does Fulgent Genetics compare to Agilon Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

How does Fulgent Genetics compare to Pediatrix Medical Group?

Which has more volatility & risk, FLGT or MD?

Do insiders & institutionals believe in FLGT or MD?

Does the media prefer FLGT or MD?

Is FLGT or MD more profitable?

Do analysts prefer FLGT or MD?

Which has higher valuation and earnings, FLGT or MD?

Summary

How does Fulgent Genetics compare to Astrana Health?

Which has more volatility and risk, ASTH or FLGT?

Which has preferable earnings and valuation, ASTH or FLGT?

Does the media prefer ASTH or FLGT?

Do analysts prefer ASTH or FLGT?

Do insiders and institutionals hold more shares of ASTH or FLGT?

Is ASTH or FLGT more profitable?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Which has preferable earnings & valuation, FLGT or GRDN?

Is FLGT or GRDN more profitable?

Do analysts recommend FLGT or GRDN?

Do institutionals & insiders hold more shares of FLGT or GRDN?

Which has more volatility & risk, FLGT or GRDN?

Does the media favor FLGT or GRDN?

Summary

How does Fulgent Genetics compare to Progyny?

Which has higher earnings and valuation, FLGT or PGNY?

Does the media refer more to FLGT or PGNY?

Which has more volatility & risk, FLGT or PGNY?

Is FLGT or PGNY more profitable?

Do institutionals and insiders have more ownership in FLGT or PGNY?

Do analysts rate FLGT or PGNY?

Summary

How does Fulgent Genetics compare to Agilon Health?

Does the media prefer AGL or FLGT?

Do analysts rate AGL or FLGT?

Is AGL or FLGT more profitable?

Which has more risk and volatility, AGL or FLGT?

Do insiders and institutionals have more ownership in AGL or FLGT?

Which has preferable valuation and earnings, AGL or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools